AVAX Technologies Announces Initiation Of Clinical Study With Autologous Ovarian Cancer Vaccine (OVax) (Medical News Today)
AVAX Technologies, Inc. (OTC Market:AVXT.OB) announces it has received FDA approval to begin enrollment into a Phase I-II clinical trial of OVax for patients with advanced, chemotherapy-refractive ovarian cancer. The study will be performed in collaboration with Cancer Treatment Centers of America, Inc (CTCA).

FDA Approvals ... Increase? (The Motley Fool)
So far in 2008, the agency's given more drugs a thumbs-up.

House Committee Asks Industry For Input On FDA Approval Process Of Follow-On Biologics (Medical News Today)
House Energy and Commerce Health Subcommittee leaders last week sent health industry stakeholders a six-page list of questions about how to create a pathway for FDA to approve follow-on biologics, CongressDaily reports. The request is the "first major movement on the issue" from subcommittee leaders since Chair Frank Pallone (D-N.J.) and ranking member Nathan Deal (R-Ga.